The engineered cell products (TEGs) possess the properties of αβ T cells, such as robust proliferation and longevity, with the additional targeting ability of the Vγ9Vδ2 TCR to BTN molecules on tumor cells without MHC restriction. This evidence concerns the gene BTN1A1 and neoplasm.